Patients can now purchase all doses of Zepbound for $499 per month or less, regardless of their health insurance status
The SURMOUNT-1 trial published in the New England Journal of Medicine demonstrated remarkable results: participants achieved an average weight loss of 15% to 20.9% of their total body weight over 72 weeks, compared to just 3.1% in the placebo group
Glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists in the treatment of obesity/metabolic syndrome, prediabetes/diabetes and non-alcoholic fatty liver diseaseCurrent evidence
Finaly Thoughts As you can see, there is not a one size fits all approach when it comes to your health
Considering the large variety of therapies available, each with different attributes and mechanisms of action, along with the heterogenous nature of T2DM, the treatment landscape is understandably complicated